Assessment of effectiveness and safety of monoclonal antibody hr3 for treating patients with glial tumors of high degree of malignancy

Authors

  • María Margarita Ríos Cabrera Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Jorge Abel Anoceto Díaz Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba
  • Raidel Oliva Valdéz Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Keywords:

glioma/therapy, antibodies, monoclonal, evaluation of results of therapeutic interventions, survival analysis

Abstract

This clinical trial will have the overall objective of determining the effectiveness and security of the use of nimotuzumab (hR3 humanized monoclonal antibody) in patients with glial tumor grade III and IV. The specific objectives are to evaluate overall survival and antitumor response, determine the progression-free survival and evaluate, in an open population, the events in patients with glial tumors with a high degree of malignancy treated with AcMhR3. Until the trial section, it was determined that the overall survival was higher for patients who received the investigational product as monotherapy. It was greater for those diagnosed with anaplastic astrocitroma than for those who had glioblastoma multiforme; in the latter patients, the survival among patients treated with monotherapy or combination therapy was equivalent. The evaluation of the objective antitumor response allowed to determine that more than half of the patients remained without disease progression to the eighth week of treatment. Progression-free survival showed that 15 patients exceeded the two-month survival, 12 patients six months, 5 patients a year and 12 patients continue the treatment. Adverse events were classified according to intensity and there were 21 of them, including 10 serious ones, six that culminated in the death of the patient, none of them related to product in research but with the base disease.

Downloads

Download data is not yet available.

Author Biographies

María Margarita Ríos Cabrera, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Licenciada en Farmacia

Jorge Abel Anoceto Díaz, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Medicina General Integral y en Neurocirugía. Máster en Bioética. Profesor Instructor de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Raidel Oliva Valdéz, Hospital Clínico Quirúrgico “Arnaldo Milián Castro”, Santa Clara, Villa Clara, Cuba

Especialista de I Grado en Neurocirugía. Profesor Instructor  de la Universidad de Ciencias Médicas de Villa Clara “Dr. Serafín Ruiz de Zárate Ruiz”.

Downloads

How to Cite

1.
Ríos Cabrera MM, Anoceto Díaz JA, Oliva Valdéz R. Assessment of effectiveness and safety of monoclonal antibody hr3 for treating patients with glial tumors of high degree of malignancy. Acta Méd Centro [Internet]. 2011 Jul. 1 [cited 2026 Feb. 11];5(3):77-8. Available from: https://revactamedicacentro.sld.cu/index.php/amc/article/view/638

Issue

Vol. 5 No. 3 (2011): July-Septembre. Special Issue of Hospital Scientifics Event

Section

Abstracts

License

Authors who have publications with this journal agree to the following terms:

  1. Authors will retain their copyright and assign to the journal the right of first publication of their work, which will simultaneously be subject to a Creative Commons License / Attribution-Noncommercial 4.0 International (CC BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
  2. Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g., depositing it in an institutional repository or publishing it in a monographic volume) as long as the initial publication in this journal is indicated.
  3. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).